Show simple item record

dc.contributor.authorManich, C. S.
dc.contributor.authorO'Shaughnessy, J.
dc.contributor.authorAftimos, P. G.
dc.contributor.authorvan den Tweel, E.
dc.contributor.authorOesterholt, M.
dc.contributor.authorEscriva-de-Romani, S. I.
dc.contributor.authorTueux, N. Q.
dc.contributor.authorTan, T. J.
dc.contributor.authorLim, J. S.
dc.contributor.authorLadoire, S.
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorCrook, T.
dc.contributor.authorStradella, A.
dc.contributor.authorBianchi, G.
dc.contributor.authorMulder, R.
dc.contributor.authorKoper, N.
dc.contributor.authorTurner, N.
dc.date.accessioned2021-10-28T09:26:18Z
dc.date.available2021-10-28T09:26:18Z
dc.date.issued2021en
dc.identifier.citationSaura Manich C, O�Shaughnessy J, Aftimos PG, van den Tweel E, Oesterholt M, Escriv�-de-Roman� SI, et al. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician�s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S1288.en
dc.identifier.doi10.1016/j.annonc.2021.08.2088en
dc.identifier.urihttp://hdl.handle.net/10541/624730
dc.description.abstractBackground [vic-]Trastuzumab duocarmazine (SYD985, Byondis B.V., NL) is a novel HER2-targeting antibody�drug conjugate comprised of trastuzumab bound to a linker drug containing duocarmycin. TULIP assessed the efficacy of SYD985 in advanced HER2-positive breast cancer. Methods The TULIP trial (NCT03262935) randomly assigned HER2-positive locally advanced or metastatic breast cancer (MBC) patients with ? 2 previous MBC regimens or previous MBC treatment with T-DM1, 2:1 between SYD985 (1.2 mg/kg q three weeks) and physician�s choice (PC) chemotherapy. The primary endpoint was progression-free survival (PFS) by blinded central review. The trial was powered to detect a Hazard Ratio (HR) of 0.65 at the P < 0.05 significance level. Secondary endpoints were investigator-assessed PFS, overall survival (OS), objective response rate (ORR), and health-related quality of life (HRQoL). Results 437 patients from 11 countries were randomized to SYD985 (n=291) or PC (n=146). Median age was 56 years, median number of prior MBC treatments was 4 [range 1-16]. Centrally reviewed median PFS was 7.0 months [95% CI 5.4-7.2] for SYD985 and 4.9 mo [4.0-5.5] for PC (HR 0.64 [0.49-0.84]; p = 0.002). Investigator-assessed PFS was also significantly improved (6.9 mo [6.0-7.2] vs 4.6 mo [4.0-5.6]; HR 0.60 [0.47-0.77]; p < 0.001). In this first analysis of OS the HR was 0.83 [0.62-1.09]; p = 0.153. No significant differences were observed in ORR or HRQoL. The most frequently reported adverse events for SYD985 were conjunctivitis (38.2%), keratitis (38.2%) and fatigue (33.3%), for PC these were diarrhoea (35.8%), nausea (31.4%) and fatigue (29.9%). Interstitial lung disease / pneumonitis was reported for 7.6% (5.2% grade 1-2) of patients treated with SYD985, including two grade 5 events. Adverse events leading to discontinuation (SYD985 35.4%, PC 10.2%) in the SYD985 group were mainly related to eye disorders (20.8%) or respiratory disorders (6.3%). Conclusions Treatment with SYD985 significantly improved PFS in comparison with standard PC and may provide a new treatment option for patients with pre-treated locally advanced or metastatic HER2-positive MBC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.08.2088en
dc.titlePrimary outcome of the phase III SYD985.002/TULIP trial comparing vic- trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast canceren
dc.typeOtheren
dc.contributor.departmentDepartment of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d�Hebron, Barcelona, Spainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2021-11-03T10:34:28Z


Files in this item

Thumbnail
Name:
AnnOncManich.pdf
Size:
81.60Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record